Companies: 10,795·Total market cap: $144.5T
Fortrea Holdings Inc.

Fortrea Holdings Inc.

FTRENASDAQHealthcare● Active
$16.65
+$0.57(+3.54%)
Market Cap$1.6B
P/E Ratio
52W High$18.67
52W Low$4.355

Fortrea Holdings Inc. (FTRE) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

ftre · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Fortrea Holdings Inc. (FTRE) measures how much investors pay for each dollar of the company's trailing earnings. FTRE's current PE ratio of N/A is calculated by dividing its stock price of $16.65 by its TTM earnings per share of -$4.90.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
16.48x
FY2027 est. EPS $1.01
Based on 7 analysts
EPS (TTM)
-$4.90
TTM · diluted EPS
PEG Ratio
-0.24
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Fortrea Holdings Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2020 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 22.0x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Fortrea Holdings Inc.
Fortrea Holdings Inc.You
FTRE
$1.6BN/A-$4.90
AnaptysBio, Inc.
AnaptysBio, Inc.
ANAB
$2.2BN/A-$0.48
ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc. Common Stock
AVBP
$1.4BN/A-$4.32
BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc.
BBOT
$625MN/A-$4.30
EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.
EYPT
$963MN/A-$3.17
Kura Oncology, Inc.
Kura Oncology, Inc.
KURA
$766MN/A-$3.18
Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc.
MRVI
$1.4BN/A-$0.90

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-10.81
2024-12-31
FY2024
$-3.67
2023-12-31
FY2023
$-0.28
2022-12-31
FY2022
15.19x$2.11-47.4%
2021-12-31
FY2021
28.87x$1.11
2020-12-31
FY2020
$-4.06

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Fortrea Holdings Inc. (FTRE) measures how much investors pay for each dollar of the company's trailing earnings. FTRE's current PE ratio of N/A is calculated by dividing its stock price of $16.65 by its TTM earnings per share of -$4.90.

PE Ratio = Stock Price ÷ EPS (TTM)
= $16.65 ÷ -$4.90 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

FTRE pe ratio · 6 questions

FTRE's current PE ratio is N/A as of 2026-06-08, based on a stock price of $16.65 and TTM EPS of -$4.90. Data sourced from Financial Modeling Prep via FTRE's SEC 10-K and 10-Q filings.

FTRE PE ratioWhat is FTRE PE ratioCurrent PE ratio of FTREFTRE PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Fortrea Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08